{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:06:08Z","timestamp":1790845568197,"version":"4.1.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,5,15]]},"DOI":"10.1093\/cid\/ciu107","type":"journal-article","created":{"date-parts":[[2014,3,5]],"date-time":"2014-03-05T23:01:35Z","timestamp":1394060495000},"page":"1386-1393","source":"Crossref","is-referenced-by-count":69,"title":["Risk Estimation for Recurrent Clostridium difficile Infection Based on Clinical Factors"],"prefix":"10.1093","volume":"58","author":[{"suffix":"Sr","given":"Ralph B.","family":"D'Agostino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylva H.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karol M.","family":"Pencina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Kean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherwood","family":"Gorbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,3,5]]},"reference":[{"key":"key\n\t\t\t\t20170522114620_CIU107C1","first-page":"75","article-title":"Clostridium difficile infection prevention: biotherapeutics, immunologics, and vaccines","volume":"13","year":"2012","journal-title":"Discov Med"},{"key":"key\n\t\t\t\t20170522114620_CIU107C2","article-title":"Clostridium difficile infections (CDI) in hospital stays, 2009. HCUP statistical brief no. 124","year":"2011"},{"key":"key\n\t\t\t\t20170522114620_CIU107C3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijantimicag.2012.01.004","article-title":"Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence","volume":"40","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20170522114620_CIU107C4","doi-asserted-by":"crossref","first-page":"E30258","DOI":"10.1371\/journal.pone.0030258","article-title":"Prediction tools for unfavorable outcomes in Clostridium difficile infection: a systematic review","volume":"7","year":"2012","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170522114620_CIU107C5","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1473-3099(11)70374-7","article-title":"Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind non-inferiority, randomized controlled trials","volume":"12","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20170522114620_CIU107C6","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection","volume":"364","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170522114620_CIU107C7","volume-title":"Applied logistic regression","year":"2000","edition":"2nd ed"},{"key":"key\n\t\t\t\t20170522114620_CIU107C8","volume-title":"Statistical methods in diagnostic medicine","year":"2003"},{"key":"key\n\t\t\t\t20170522114620_CIU107C9","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/sim.3106","article-title":"Comments on integrated discrimination and net reclassification improvements\u2014practical advice","volume":"27","year":"2008","journal-title":"Stat Med"},{"key":"key\n\t\t\t\t20170522114620_CIU107C10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/sim.2929","article-title":"Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond","volume":"27","year":"2008","journal-title":"Stat Med"},{"key":"key\n\t\t\t\t20170522114620_CIU107C11","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/sim.4348","article-title":"Novel metrics for evaluating improvement in discrimination: net reclassification and integrated discrimination improvement for normal variables and nested models","volume":"31","year":"2012","journal-title":"Stat Med"},{"key":"key\n\t\t\t\t20170522114620_CIU107C12","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/sim.1742","article-title":"Presentation of multivariate data for clinical use: the Framingham Study risk score functions","volume":"23","year":"2004","journal-title":"Stat Med"},{"key":"key\n\t\t\t\t20170522114620_CIU107C13","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care","volume":"117","year":"2008","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170522114620_CIU107C14","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1086\/587654","article-title":"The case for vancomycin as the preferred drug for treatment of Clostridium difficile infection","volume":"46","year":"2008","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170522114620_CIU107C15","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1086\/519265","article-title":"A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity","volume":"45","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"suppl 2","key":"key\n\t\t\t\t20170522114620_CIU107C16","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1093\/cid\/cis335","article-title":"Burden of Clostridium difficile on the healthcare system","volume":"55","year":"2012","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170522114620_CIU107C17","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jhin.2009.10.016","article-title":"Economic healthcare costs of Clostridium difficile infection: a systematic review","volume":"74","year":"2010","journal-title":"J Hosp Infect"},{"key":"key\n\t\t\t\t20170522114620_CIU107C18","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.3748\/wjg.15.1554","article-title":"Clostridium difficile associated infection, diarrhea and colitis","volume":"15","year":"2009","journal-title":"World J Gastroenterol"},{"key":"key\n\t\t\t\t20170522114620_CIU107C19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jinf.2010.03.025","article-title":"A review of mortality due to Clostridium difficile infection","volume":"61","year":"2010","journal-title":"J Infect"},{"key":"key\n\t\t\t\t20170522114620_CIU107C20","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/nrmicro2164","article-title":"Clostridium difficile infection: new developments in epidemiology and pathogenesis","volume":"7","year":"2009","journal-title":"Nat Rev Microbiol"},{"key":"key\n\t\t\t\t20170522114620_CIU107C21","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1128\/JCM.38.6.2386-2388.2000","article-title":"Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea","volume":"38","year":"2000","journal-title":"J Clin Microbiol"},{"issue":"suppl C","key":"key\n\t\t\t\t20170522114620_CIU107C22","first-page":"41","article-title":"Treatment of Clostridium difficile infection","volume":"41","year":"1998","journal-title":"J Antimicrob Chemother"},{"issue":"suppl 2","key":"key\n\t\t\t\t20170522114620_CIU107C23","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1093\/cid\/cis357","article-title":"Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin","volume":"55","year":"2012","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170522114620_CIU107C24","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1128\/JCM.42.8.3635-3643.2004","article-title":"Molecular epidemiology of hospital-associated and community-acquired Clostridium difficile infection in a Swedish county","volume":"42","year":"2004","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20170522114620_CIU107C25","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1128\/JCM.41.7.3413-3414.2003","article-title":"Molecular analysis of Clostridium difficile strains isolated from 18 cases of recurrent Clostridium difficile-associated diarrhea","volume":"41","year":"2003","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20170522114620_CIU107C26","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1086\/513755","article-title":"Effect of vancomycin on intestinal flora of patients who previously received antimicrobial therapy","volume":"25","year":"1997","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170522114620_CIU107C27","first-page":"739","article-title":"Guidelines for the diagnosis and management of Clostridium difficile\u2013associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee","volume":"92","year":"1997","journal-title":"Am J Gastroenterol"},{"issue":"suppl 2","key":"key\n\t\t\t\t20170522114620_CIU107C28","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1093\/cid\/cis338","article-title":"Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI","volume":"55","year":"2012","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170522114620_CIU107C29","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1111\/j.1572-0241.2002.05839.x","article-title":"Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease","volume":"97","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170522114620_CIU107C30","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1086\/501553","article-title":"Recurrent Clostridium difficile disease: epidemiology and clinical characteristics","volume":"20","year":"1999","journal-title":"Infect Control Hosp Epidemiol"},{"key":"key\n\t\t\t\t20170522114620_CIU107C31","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1086\/501126","article-title":"Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada","volume":"42","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"pt 11","key":"key\n\t\t\t\t20170522114620_CIU107C32","first-page":"3216","article-title":"Long-term impacts of antibiotic exposure on the human intestinal microbiota","volume":"156","year":"2010","journal-title":"Microbiology"},{"issue":"pt 11","key":"key\n\t\t\t\t20170522114620_CIU107C33","first-page":"3354","article-title":"A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin","volume":"156","year":"2010","journal-title":"Microbiology"},{"issue":"suppl 1","key":"key\n\t\t\t\t20170522114620_CIU107C34","first-page":"S33","article-title":"Recurrent Clostridium difficile infection: causality and therapeutic approaches","volume":"33","year":"2009","journal-title":"Int J Antimicrob Agents"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","deposited":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T21:48:50Z","timestamp":1597528130000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article-lookup\/doi\/10.1093\/cid\/ciu107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,5]]},"references-count":34,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2014,3,5]]},"published-print":{"date-parts":[[2014,5,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciu107","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718299600.793495450","asserted-by":"object"}]},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,5]]}}}